Bio-Techne Corp Q1 2022 Earnings Call Summary

The following is excerpted from the question-and-answer section of the transcript.

Question: Jacob K. Johnson - Stephens Inc., Research Division - Analyst : Maybe, Chuck, on the cell and gene therapy side, I think you've been clear that end market is an opportunity for you and a lot of initiatives there. But it seems like yourself and maybe some others saw some pickup in activity from that end market this quarter. Is there something that's changed in the end market? Or was the kind of performance you put up this quarter, just a function of kind of your internal efforts and GMP coming.

Question: Jacob K. Johnson - Stephens Inc., Research Division - Analyst : Got it. That makes sense. I guess maybe, Chuck, the natural follow-up to that, I guess, you've got the capabilities you have today, but it seems to me, you'd probably like to add to that at some point. Can you just talk about your thoughts on adding cell and gene therapy capabilities, the potential to do that organically and maybe thoughts on inorganic efforts there as well.